|
|
Article: Zogenix Announces sumatriptan DosePro(TM) NDA Accepted for Filing by FDA.
- Article from:
- Business Wire
- Article date:
- March 19, 2008
CopyrightCOPYRIGHT 2008 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN DIEGO -- Zogenix, Inc. ("Zogenix"), a private, specialty pharmaceutical company, today announced that its New Drug Application (NDA) for sumatriptan DosePro[TM] has been accepted for filing by the U.S. Food and Drug Administration (FDA). Zogenix is seeking marketing approval from the FDA of sumatriptan DosePro for the acute treatment of migraine attacks with or without aura and cluster headache episodes. The FDA will take action on its application in late 2008.
Sumatriptan DosePro (formerly known as Intraject([R]) sumatriptan) utilizes Zogenix's proprietary DosePro needle-free drug delivery system to subcutaneously administer sumatriptan for the treatment of ...